Pantoprazole

Proton pump inhibitors

ATC code: A02BC02 (Pantoprazole)

Mechanism of action

Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells. Same mechanism as omeprazole. Pantoprazole's advantage is weaker CYP2C19 inhibition, making it preferred in patients on clopidogrel. Omeprazole and esomeprazole inhibit CYP2C19 more potently and may reduce the antiplatelet effect of clopidogrel.

Indications

Gastroesophageal reflux disease

First line

First-line GERD therapy. PPIs are the most effective agents for acid suppression. Pantoprazole 40 mg once daily 30 minutes before breakfast. Course 4–8 weeks, then attempt dose reduction or on-demand dosing.

NSAID gastropathy prophylaxis

First line

First-line prophylaxis of gastropathy in patients on long-term NSAIDs with risk factors – age over 65, ulcer history, concomitant anticoagulants or corticosteroids. Pantoprazole 20 mg once daily for the duration of NSAID therapy.

Peptic ulcer disease

First line

First-line for peptic ulcer disease. Duodenal ulcer course is 4 weeks, gastric ulcer 8 weeks. In H. pylori eradication, any PPI at double dose twice daily. Pantoprazole is preferred in patients on clopidogrel after coronary stenting.

Practical notes

Timing and administration

Take 30 minutes before the first meal. The proton pump is activated by meal-stimulated signaling, and the drug needs to be circulating at that point. Swallow the tablet whole, do not crush – the enteric coating protects against degradation in gastric acid.

Special situations

When combined with clopidogrel, pantoprazole is preferred over other PPIs. Omeprazole and esomeprazole are potent CYP2C19 inhibitors and reduce conversion of clopidogrel to its active metabolite. The FDA issued a warning about this interaction for omeprazole. Pantoprazole shows no clinically significant interaction with clopidogrel.

Safety

Contraindications

Hypersensitivity to PPIs

Serious adverse effects

Clostridioides difficile-associated diarrhea
Hypomagnesemia with long-term use (over 1 year)
Increased fracture risk with long-term use – hip, wrist, spine
Vitamin B12 deficiency with use over 2 years
Acute interstitial nephritis (rare)

Common adverse effects

Headache
Diarrhea
Nausea
Flatulence
Abdominal pain

PregnancyFDA B

FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.